Edwards Lifesciences (EW) Long-Term Deferred Tax (2009 - 2026)

Edwards Lifesciences has reported Long-Term Deferred Tax for 18 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 6.84% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 6.84% YoY), and the FY2025 full-year result was $1.1 billion, up 14.72% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $1.1 billion, down from $1.1 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $1.1 billion in Q4 2025, with the low at $294.9 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $760.3 million, with a median of $776.7 million recorded in 2024.
• Year-over-year, Long-Term Deferred Tax jumped 98.54% in 2023 and climbed 6.84% in 2026.
• Tracing EW's Long-Term Deferred Tax over 5 years: stood at $484.0 million in 2022, then surged by 54.83% to $749.4 million in 2023, then jumped by 32.39% to $992.1 million in 2024, then grew by 14.72% to $1.1 billion in 2025, then slipped by 3.51% to $1.1 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison